Posted by Michael Wonder on 30 Nov 2021
Junshi Biosciences announces approval of supplemental new drug application by NMPA for toripalimab in combination with cisplatin and gemcitabine as first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma
30 November 2021 - Fourth approved indication for toripalimab.
Shanghai Junshi Biosciences announced today that the National Medical Products Administration of China has approved its supplemental new drug application for toripalimab in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic nasopharyngeal carcinoma.
